Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.78 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | FGR | P09769 | 1/20 | 0.60 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | FER | P16591 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.60 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.60 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.60 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2507333 | 0.93 | SYK (0.76) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2499817 | 0.92 | SYK (0.73) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2045114 | 0.92 | SYK (0.72) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2015947 | 0.91 | SYK (0.82) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL13518073 | 0.91 | SYK (0.82) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2016249 | 0.91 | SYK (0.82) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2505065 | 0.91 | SYK (0.82) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2054139 | 0.91 | SYK (0.82) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2016556 | 0.89 | SYK (0.79) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2504461 | 0.89 | SYK (0.79) | SYKJAK2NTRK1FYNFGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513098-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885JAK2 23/4885NTRK1 3823/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | SYK 1/4885JAK2 23/4885NTRK1 3823/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885JAK2 23/4885NTRK1 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.